The oncology nutrition market size is projected to expand from USD 2.77 billion in 2025 and USD 2.94 billion in 2026 to USD 3.96 billion by 2031, registering a CAGR of 6.12% between 2026 to 2031. This report is Segmented by Cancer Type (Head & Neck Cancer, Stomach & Gastrointestinal Cancers, and More), Nutrition Type (Enteral Nutrition, Parenteral Nutrition), Formula Type (Standard Formula, and More), End-User (Hospitals, Home Care, Specialty Oncology Clinics), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Radiation-induced mucositis affects up to 80% of head-and-neck patients, encouraging early prophylactic feeding-tube placement and elemental formula preference because of reduced digestive effort. Lung-cancer regimens elevate resting energy expenditure by 10-15%, and clinicians increasingly prescribe immunonutrition formulas to counter catabolism, though consensus on protocol specifics remains under debate. Stomach and gastrointestinal cancers add notable volume through long-term support needs after resections, while hematologic malignancies sustain parenteral demand during intensive chemotherapy phases.
Enteral products accounted for 75.54% of Oncology nutrition market size in 2025 as infection-avoidance benefits and lower costs underpin prescribing norms. Catheter bloodstream infections occur 40-50% less often with enteral routes, and gut-mediated immunity is thought to aid checkpoint-inhibitor efficacy. Parenteral nutrition, although holding only 24.46% share, is growing at 6.65% CAGR as advanced lipid emulsions cut inflammatory complications and home-infusion platforms broaden eligibility.
Reimbursement policy significantly influences modality choice. U.S. Medicare’s 2025 update waiving prior authorization for weight-loss cases above 10% boosted enteral discharges, whereas parenteral approvals still demand detailed malabsorption documentation. Cost remains a stark differential: USD 50-100 per day for enteral versus USD 150-300 for parenteral, steering hospital formularies toward enteral default except when contraindicated.
Europe ranked second, led by Germany, the United Kingdom, France, Italy, and Spain. Germany’s universal insurance reimburses home enteral nutrition comprehensively, driving per-capita consumption rates among the world’s highest. The United Kingdom’s National Health Service grants coverage to select tumor types only, making patient advocacy pivotal to policy expansion. Eastern European markets are rising as oncology infrastructure modernizes and EU funding improves supply chains.
Asia-Pacific is projected to deliver a 7.12% CAGR through 2031. China’s regulator approved multiple enteral products in 2024-2025, and its aging population is driving lung, gastric, and colorectal volume. India struggles with reimbursement gaps but flagship tertiary hospitals in metro areas are aligning with global nutrition guidelines. Japan’s universal payer system underwrites home enteral therapy, supporting stable demand even as total population contracts. Mature markets such as Australia and South Korea enjoy high adoption, while Southeast Asia remains nascent because of affordability barriers.
Global Oncology Nutrition Market Trends and Insights
Rising Prevalence of Cancer Worldwide
Global cancer incidence stood at 20 million new cases in 2022 and is projected to soar to 35 million per year by 2050, a 75% upswing linked to aging populations, urban lifestyles, and broader screening programs. Forty-to-eighty percent of patients experience cancer-related malnutrition, which directly undermines chemotherapy completion and overall survival. Asia-Pacific is registering the fastest case growth, including sharp lung-cancer increases among never-smoking women exposed to air pollution. Head-and-neck cancers remain prevalent in South Asia because of tobacco and betel-nut habits, amplifying dysphagia-driven nutrition needs. Health systems are embedding screening tools such as the Patient-Generated Subjective Global Assessment to close the care gap.Shift from Parenteral to Enteral Nutrition
Clinical evidence confirms that enteral routes cut catheter-related bloodstream infections by 40-50% compared with parenteral alternatives, a safety edge that is reshaping protocol templates in oncology wards. Enteral feeding maintains gut integrity and commensal microbiota, factors now linked to superior responses to immune-checkpoint inhibitors. Medicare dropped prior-authorization hurdles for home enteral nutrition in 2025, accelerating U.S. uptake. Device makers have introduced low-profile gastrostomy buttons and nasojejunal tubes that improve comfort and aesthetics, important for younger hematologic-oncology patients. Parenteral nutrition remains essential for severe mucositis and bowel obstruction, but its use is increasingly confined to specific complications.High Cost of Premium Oncology Nutrition Products
Immunonutrition formulas retail at USD 8-15 per serving, translating to USD 240-450 in monthly spending for patients requiring 1,500-2,000 kcal exclusively from enteral sources. In a 2024 U.S. survey, 38% of oncology patients reduced or discontinued supplements because of price, with Medicare beneficiaries in the coverage gap most affected. Generic polymeric formulas are cheaper but lack glutamine and omega-3 features that modulate inflammation, limiting their appeal to clinicians. In low-income regions, per capita health budgets of USD 50-200 make commercial products unattainable, forcing reliance on blenderized diets that frequently miss protein and micronutrient targets. Manufacturers wrestle with price-volume trade-offs: cutting prices widens access but dilutes margins on complex, quality-controlled supply chains.Other drivers and restraints analyzed in the detailed report include:
- Growing Adoption of Home-Based Enteral Feeding Devices
- Product Innovation - Elemental & Immuno-Modulating Formulas
- Reimbursement Gaps for Outpatient Nutrition Therapy
Segment Analysis
Head-and-neck malignancies captured 28.54% of Oncology nutrition market share in 2025, cementing their position as the largest revenue generator. Severe dysphagia, odynophagia, and xerostomia often last beyond the radiation window, driving extended gastrostomy dependence and sustained formula volumes. The Oncology nutrition market size allocated to lung cancer is projected to advance at a 7.25% CAGR through 2031, reflecting rising non-smoking-related incidence and the metabolic demands of PD-1/PD-L1 checkpoint combinations.Radiation-induced mucositis affects up to 80% of head-and-neck patients, encouraging early prophylactic feeding-tube placement and elemental formula preference because of reduced digestive effort. Lung-cancer regimens elevate resting energy expenditure by 10-15%, and clinicians increasingly prescribe immunonutrition formulas to counter catabolism, though consensus on protocol specifics remains under debate. Stomach and gastrointestinal cancers add notable volume through long-term support needs after resections, while hematologic malignancies sustain parenteral demand during intensive chemotherapy phases.
Enteral products accounted for 75.54% of Oncology nutrition market size in 2025 as infection-avoidance benefits and lower costs underpin prescribing norms. Catheter bloodstream infections occur 40-50% less often with enteral routes, and gut-mediated immunity is thought to aid checkpoint-inhibitor efficacy. Parenteral nutrition, although holding only 24.46% share, is growing at 6.65% CAGR as advanced lipid emulsions cut inflammatory complications and home-infusion platforms broaden eligibility.
Reimbursement policy significantly influences modality choice. U.S. Medicare’s 2025 update waiving prior authorization for weight-loss cases above 10% boosted enteral discharges, whereas parenteral approvals still demand detailed malabsorption documentation. Cost remains a stark differential: USD 50-100 per day for enteral versus USD 150-300 for parenteral, steering hospital formularies toward enteral default except when contraindicated.
Complete Report Scope:
- By Cancer Type
- Head & Neck Cancer
- Stomach & Gastrointestinal Cancer
- Blood Cancer
- Breast Cancer
- Lung Cancer
- Other Cancers
- By Nutrition Type
- Enteral Nutrition
- Parenteral Nutrition
- By Formula Type
- Standard Formula
- Elemental / Semi-elemental Formula
- Disease-specific / Immunonutrition Formula
- By End User
- Hospitals
- Home Care Settings
- Specialty Oncology Clinics
- Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 39.23% of global revenue in 2025, anchored by Medicare coverage, two-million-plus annual cancer diagnoses, and entrenched clinical pathways that mandate nutrition screening at each chemotherapy cycle. The 2025 removal of prior-authorization requirements for home enteral therapy simplified discharge and swelled supplier order volumes. Canada’s coverage is province-specific, with Ontario and British Columbia offering the most generous benefits, while Mexico’s public systems lag, propelling private insurance uptake.Europe ranked second, led by Germany, the United Kingdom, France, Italy, and Spain. Germany’s universal insurance reimburses home enteral nutrition comprehensively, driving per-capita consumption rates among the world’s highest. The United Kingdom’s National Health Service grants coverage to select tumor types only, making patient advocacy pivotal to policy expansion. Eastern European markets are rising as oncology infrastructure modernizes and EU funding improves supply chains.
Asia-Pacific is projected to deliver a 7.12% CAGR through 2031. China’s regulator approved multiple enteral products in 2024-2025, and its aging population is driving lung, gastric, and colorectal volume. India struggles with reimbursement gaps but flagship tertiary hospitals in metro areas are aligning with global nutrition guidelines. Japan’s universal payer system underwrites home enteral therapy, supporting stable demand even as total population contracts. Mature markets such as Australia and South Korea enjoy high adoption, while Southeast Asia remains nascent because of affordability barriers.
List of Companies Covered in this Report:
- Abbott Laboratories
- Ajinomoto Co., Inc.
- Avanos Medical
- B. Braun
- Baxter
- Cardinal Health
- Danone
- Fresenius
- Global Health Product
- Grifols
- Hormel Foods
- Kate Farms
- Meiji Holdings Co., Ltd.
- Moog
- Nestle S.A.
- Otsuka Pharmaceutical Co. Ltd.
- ProDiet
- Reckitt Benckiser Group
- Victus
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Ajinomoto Co., Inc.
- Avanos Medical
- B. Braun SE
- Baxter International Inc.
- Cardinal Health
- Danone SA (Nutricia)
- Fresenius SE & Co. KGaA (Fresenius Kabi)
- Global Health Products, Inc.
- Grifols S.A.
- Hormel Foods Corporation
- Kate Farms
- Meiji Holdings Co., Ltd.
- Moog Inc.
- Nestle S.A.
- Otsuka Pharmaceutical Co. Ltd.
- ProDiet
- Reckitt Benckiser Group plc
- Victus, Inc.
